for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Opioid makers need plan to curb risks: FDA

WASHINGTON (Reuters) - U.S. regulators will require 16 manufacturers of brand-name and generic opioid painkillers to impose stronger measures to curb misuse and abuse, the U.S. Food and Drug Administration said on Monday.

The FDA sent letters inviting the companies to a meeting in March to discuss ways to reduce dangerous use of the medicines. Companies that received the letters include Johnson & Johnson, King Pharmaceuticals Inc, Endo Pharmaceuticals Holding Inc and privately held Purdue Pharma.

Reporting by Lisa Richwine and Susan Heavey; Editing by Tim Dobbyn

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up